FK 506 In clinical organ transplantation
نویسندگان
چکیده
Fung 11, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, Jordan M, Armitage J, Jain A, Martin M, Bronster 0, Stieber A, Kormos R, Selby R, Gordon R, Starzl TE. FK506 in clinical organ transplantation. John J. Fung, Kareem Abu-Elmagd, Saloro Todo, Ronald Shapiro, Andreas Tzakis, Mark Jordan, John Armitage, Ashok Jain, Maureen Martin, Oscar Bronster, Andrei Stieber, Robert Kormos, Robert Selby, Robert Gordon and Thomas E. Starzl
منابع مشابه
Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression.
POSlTRANSPLANT Iymphoproliferative disease (PTLD) is a well-recognized complication of immunosuppression. I Previous reports of patients immunosuppressed with cyclosporine (eyA) revealed a 1.7% incidence of PTLD in solid-organ transplant recipients and a strong association with the Epstein-Barr virus «EBV). ~ The use of FK 506 in clinical trials has resulted in improved patient and graft surviv...
متن کاملCorrelation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection.
FK 506, a novel immunosuppressive agent, was first used to reverse rejection in liver recipients who had failed to respond to conventional therapy.' The successful outcome of the initial study has led to clinical trials of FK 506 as the primary immunosuppressive agent for liver allografts and other organ transplants. 2-4 Ongoing studies include dosage protocols for optimal immunosuppression wit...
متن کاملLiver, kidney, and thoracic organ transplantation under FK 506.
The new immunosuppressive drug FK 506 was used from the outset with low doses of prednisone to treat 120 recipients of primary liver grafts and 20 more patients undergoing liver retransplantation. The patient survival rate after 2 to 8 months in the primary liver transplantation series is 93.3%, with original graft survival of 87.5%. Of the 20 patients in the hepatic retransplant series, 17 (85...
متن کاملOne thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.
FK 506 (Tanolimus. Prograf'") has been recently approved by the Food and Drug Administration (FDA) for baseline immunosuppression following orthotopic liver transplantation (OLT). The drug was first used clinically in 1989. 1 and I year later at the Thirteenth International Congress of Transplantation Society. San Francisco. CA 1990. extensive reports were given from our center describing the p...
متن کاملSelected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics.
FK 506 is a superior immunosuppressive agent that should improve the grafting of organs that already are part of our every day transplant practices, as well as those which are presently impractical. Immune intervention for serious autoimmune diseases also should be a more attractive option with this drug. Lessons are still being learned about dosage and what determines safe dose schedules. At a...
متن کاملSuccessful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy.
A LTHOUGH small bowel transplantation is the physiologic treatment of the short bowel syndrome, Its clinical implementation awaits development of immunosuppressive regimens that ensure satisfactory control of graft rejection. Agents such as Cy A and corticosteroids are useful for transplantation of most other vascularized organ allografts. However, rejection of the transplanted small intestine ...
متن کامل